


DISCLAIMER NOTICE



THIS DOCUMENT IS BEST
QUALITY AVAILABLE. THE COPY
FURNISHED TO DTIC CONTAINED
A SIGNIFICANT NUMBER OF
PAGES WHICH DO NOT
REPRODUCE LEGIBLY.

AD679753

Copyright, 1968, by the Society for Experimental Biology and Medicine
Reprinted from PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE
1968, v128, 1168-1173

**A Genus Specific Complement Fixation Antigen from
*Neisseria meningitidis** (33221)**

E. A. EDWARDS AND L. F. DEVINE (Introduced by J. C. Holper)
*Immunology Division and Bacteriology Division, Naval Medical Research Unit No. 4,
Great Lakes, Illinois 60088*

The serological diagnosis of meningococcal meningitis has been studied by a number of workers during the past 60 years using the precipitin test (1), bactericidal and agglutination test (2), and opsonin test (3). Additional epidemiological information on meningococcal meningitis has been obtained by fermentation and agglutination reactions of isolates from the patient and his contacts (4). The complement fixation (CF) test has seldom been used for the diagnosis of meningococcal meningitis. Cruickshank (5) was one of the first to use the CF test for the diagnosis of meningococcal disease. Ross and Stevenson (6) assessed

the use of the CF test in diagnosing meningococcal 'aseptic' meningitis. Recently, the cell wall has been used as a CF antigen by

* This study was done in connection with Research Project No. M 4305.01-1001, Bureau of Medicine and Surgery, Navy Department, Washington, D. C. The opinions and assertions contained herein are those of the authors and are not to be construed as official or as reflecting the views of the Navy Department or the Naval Service at large.

The experiments reported herein were conducted according to the principles enunciated in "Guide for Laboratory Facilities and Care" prepared by the Committee on the Guide for Laboratory Animal Resources, National Academy of Sciences—National Research Council.

N. meningitidis COMPLEMENT FIXATION ANTIGEN

Sanborn and Vedros (7). The antigens used by these investigators were somewhat group-specific, but lacked broad group specificity.

This report describes a method for producing a potent CF antigen which was easily produced in large quantities, not anticomplementary, and reacted specifically with antisera to *Neisseria* species in high titer. Comparison was also made between seroconversions employing this CF antigen and bacterial isolations from recruits at the Naval Training Center, Great Lakes, Illinois.

Materials and Methods. Antigen preparation. *Neisseria meningitidis* groups A (CL-4),¹ B (16B6),¹ C (PTS-5),¹ and strains Bo¹ (8,9), 29E,² B (Scarborough),³ 135,² and Z² (10) were used in preparing the CF antigens. One ml of each group of an 8-hour culture grown in Mueller-Hinton broth (Difco) was inoculated separately into 250 ml of Mueller-Hinton broth, incubated for 18 hours at 37°C in a Psychrotherm Incubator-Shaker⁴ (170-200 rotations a minute) in normal atmosphere (11). The cultures were then killed with a final concentration of 1% beta propiolactone overnight at 6°C. The supernatant fluid recovered after centrifugation (600g) was saturated with ammonium sulfate crystals (510 gm/liter) and allowed to set overnight at 6°C with an occasional shaking. The sediment from each 250 ml of original culture was collected after centrifugation (1000g) and resuspended in 40 ml of 0.15 M NaCl (saline). This crude material was dialyzed against excess amounts of saline until free of ammonium sulfate (24-48 hours). This material was the CF antigen. Further centrifugation reduced turbidity, but a 4-fold loss in potency occurred. The turbidity of the crude antigen did not interfere with determining the CF end points. Therefore, the crude antigen was used for the data presented in this report. Tests for antigen

anticomplementariness and potency were performed by standard procedures (12) adapted to the microtechnique (13). Two exact units of complement were used. The primary incubation was for 18 hours at 6°C.

Recruit sera. Blood was collected from recruits upon entering recruit training, at 5 weeks and at 9 weeks of training. Also, recruits who were admitted to the Naval Hospital, Great Lakes with the clinical diagnosis of meningitis were bled upon admission and at approximately weekly intervals for at least 4 weeks. Nasopharyngeal and spinal fluid cultures for *N. meningitidis* were also made on each recruit upon admission to the hospital. Sera were separated from clotted blood and stored at -20°C until tested.

Hyperimmune rabbit serum. Hyperimmune, group-specific antisera were obtained from Difco *N. meningitidis* group A Lot No. 499231, group B Lot No. 512116 and group C Lot No. 511599. Hyperimmune rabbit sera for *N. meningitidis* strains Bo, 135, 29E, and Z were made in this laboratory using the following procedure: the meningococci were grown in Mueller-Hinton broth as described for making CF antigen. The cells were harvested after 6-hours incubation, washed once in saline, and resuspended in 0.5% formaldehyde in saline. New Zealand white rabbits were inoculated intraperitoneally (i.p.) with 1 ml (10⁸ organisms) Monday, Wednesday, and Friday of the first week; at similar intervals with 10⁸ organisms during the second and third weeks; permitted to rest one week; then inoculated with 1 ml of 10⁸ viable organisms intravenously (i.v.) each week until the rabbits developed a satisfactory antiserum for the slide bacterial agglutination test. Rarely were more than 2 i.v. injections required before a high titered antiserum was obtained. Hyperimmune *N. gonorrhoeae* rabbit serum was supplied by William Peacock, Jr., Venereal Disease Research Laboratory, CDC. Hyperimmune *Hemophilus influenzae* and *Diplococcus pneumoniae* antisera were Lot Nos. 496278 and 497496, respectively, from Difco. Sera from patients with *Salmonella typhi* disease were supplied by Miss Jean Koehler, State

¹ Stock cultures obtained from N. Vedros, LT MSC USN, NAMRU-1, Oakland, California.

² Strains supplied by Dr. M. Arstenstein, WRAIR, Washington, D. C.

³ Strain isolated from spinal fluid supplied by one of the authors (LFD).

⁴ New Brunswick Scientific Company, New Brunswick, New Jersey.

N. meningitidis COMPLEMENT FIXATION ANTIGEN

TABLE I. Complement Fixation Titers* of Various Hyperimmune Rabbit *N. meningitidis* Antisera Using Antigen Prepared from Different *N. meningitidis* Groups and Strains.

Immune serum	CF antigen prepared from <i>N. meningitidis</i> groups and strains (4 antigen units/unit volume)						
	A	B	C	Bo	29E	135	Z
<i>N. meningitidis</i> group A	128	128	128	64	128	64	128
group B	128	256	128	256	256	256	256
group C	64	64	64	128	64	256	256
strain Bo	64	128	64	128	128	256	256
strain 29E	128	512	128	128	128	512	256
strain Z	64	128	64	64	64	256	256
strain 135	64	64	64	64	32	128	256
<i>N. gonorrhoeae</i>	32	64	32	64	64	32	32
<i>N. catarrhalis</i>	ND ^b	16	16	16	32	32	ND
<i>N. flava</i>	32	16	64	64	64	64	ND
<i>N. flavescens</i>	32	64	64	32	64	64	ND
<i>N. sicca</i>	32	16	32	32	16	32	ND
<i>N. perflava</i>	16	16	64	64	128	64	ND
<i>N. subflava</i>	ND	32	64	32	32	64	ND
<i>D. pneumoniae</i>	4	<4	4	4	8	<4	4
<i>H. influenzae</i>	<4	4	4	<4	8	4	<4
<i>S. typhi</i> (O=1:2530; H=1:80)	4	4	8	4	4	4	8
<i>S. typhi</i> (O=1:640; H=1:5120)	4	4	4	4	4	4	4

* The reciprocal of initial dilution of serum showing a 4+ fixation.

^b Not done.

Laboratory of Hygiene, Madison, Wisconsin. All human and rabbit sera were heated at 56°C just prior to testing.

N. meningitidis isolation. Nasopharyngeal cultures were taken with a bent cotton swab and inoculated immediately on Mueller-Hinton medium (Difco) containing 10 µg/ml of ristocetin (Difco) and 25 units/ml of polymyxin B. Culture media were maintained above 30°C in an insulated box during transport to the laboratory. The inoculum was then streaked with a bacteriological loop for isolation of colonies and incubated for 18-24 hours in 5% CO₂ atmosphere at 37°C.⁵ Organisms from colonies morphologically resembling *N. meningitidis* were tested by slide agglutination using groups A, B, C, and D rabbit antisera (CDC) and rabbit antisera prepared in this laboratory for the

⁵ Model 1237 Hotpack Incubator, Hotpack Corp., Philadelphia, Penn.

"nontypable" meningococcal strains. All isolates agglutinating as *N. meningitidis* were confirmed as such by the usual sugar fermentations and oxidase tests.

Results. The genus specificity of the CF antigen is shown in Tables I and II. Antigens were extracted from 3 groups and 4 strains (nontypables) of *N. meningitidis*. All antigens fixed complement with 7 *N. meningitidis* antisera and antisera to 7 other species of the Genus *Neisseria*. All titers were within the limitation of error of the test except 2 which were 1-tube dilution outside the acceptable range of error. The antisera to *D. pneumoniae*, *H. influenzae*, *S. typhi* O and H antigens fixed complement at a titer of 1:8 or less.

The sera from 3 recruits who became carriers of *N. meningitidis* strain Bo during recruit training were tested for CF antibody with antigens from each of 5 different groups

N. meningitidis COMPLEMENT FIXATION ANTIGEN

TABLE II. Complement Fixation Titers* of Various Preparations of *N. meningitidis* CF Antigens Using Homologous and Heterologous Hyperimmune Rabbit *N. meningitidis* Groups and Strains.

Hyperimmune sera	CF antigen prepared from <i>N. meningitidis</i> groups and strains						
	A	B	C	Bo	29E	135	Z
<i>N. meningitidis</i> group A	128	128	128	64	64	64	128
group B	128	256	128	256	256	256	256
group C	64	64	128	128	64	128	128
strain Bo	32	128	64	128	64	128	128
strain 29E	128	512	128	128	512	256	512
strain 135	64	64	64	64	64	128	256
strain Z	64	128	64	64	64	256	512
<i>N. gonorrhoeae</i>	64	256	64	64	512	256	256

* The reciprocal of the highest dilution of antigen showing a 4+ fixation in the presence of 4 CF units of antibody.

or strains of *N. meningitidis* (Table III). The titer of each serum against each of 5 antigens were essentially identical. Sera from 4 recruits who had clinical meningitis were tested against 6 CF antigens, and showed the same seroresponse to each of the antigens (Table IV). These data indicate that by the seventh day post-hospitalization for meningococcal disease, a substantial increase in antibody titer is shown with a peak titer occurring by day 21. Two of these cases were due to *N. meningitidis* group C, one was due to strain Bo, and one (No 749) had no isolate. Each antigen was made

from a different *N. meningitidis* group or strain.

The correlation of 4-fold or greater increase in titers to CF antigen with acquisition of *N. meningitidis*, as determined by isolation, is shown in Table V. The correlation is highly significant ($p = < .0001$).

Discussion. The appearance of specific antibody during convalescence from meningococcal disease was described by Thomas *et al.* (2). Studies have shown that the acquisition of meningococcus in the nasopharynx is followed by the development of meningococcal antibody (7, 14, 15). These

TABLE III. Comparison of Complement Fixation Serum Antibody Titers* of Navy Recruit Carriers of *N. meningitidis* Strain Bo Using 5 Complement Fixing Antigens.

Study recruit no.	Week in training	Sample no.	CF antigens for <i>N. meningitidis</i> groups or strains				
			29E	C	B (Scarborough)	B (16B6)	Bo
1083	0	1	1:4	<1:4	<1:4	<1:4	<1:4
	5	2	1:4	<1:4	<1:4	<1:4	1:4
	9	3	1:64	1:32	1:32	1:64	1:64
1090	0	1	<1:4	<1:4	<1:4	<1:4	<1:4
	5	2	1:64	1:32	1:64	1:64	1:32
	9	3	1:32	1:16	1:32	1:32	1:16
1123	0	1	<1:4	<1:4	<1:4	<1:4	<1:4
	5	2	<1:4	<1:4	<1:4	<1:4	<1:4
	9	3	1:16	1:16	1:32	1:32	1:16

* Serum titers expressed as the reciprocal of the highest dilution giving a 4+ fixation in the presence of 4 units of antigen.

N. meningitidis COMPLEMENT FIXATION ANTIGEN

TABLE IV. Comparison of Complement Fixation Serum Antibody Titers* in Navy Recruits with Clinical Meningitis, Using 6 Complement Fixation Antigens.

Patient	Sample post-admission day	CF antigens from <i>N. meningitidis</i> groups or strains					
		A	B	C	29E	135	Bo
286	0	<	4	4	4	4	4
	10	128	256	128	256	256	128
	19	256	128	128	128	128	128
	31	64	64	128	64	64	64
521	0	<	<4	<4	<4	4	<4
	7	8	16	16	8	8	8
	14	32	64	64	64	64	64
	21	32	64	64	64	32	64
782	0	<	<4	<4	<4	4	<4
	7	32	64	128	64	64	64
	14	32	64	128	64	32	64
	21	32	64	128	32	64	64
749	0	<	<4	<4	<4	<4	<4
	7	4	4	4	4	4	4
	14	64	128	128	128	64	64
	21	32	64	64	64	32	64

* Reciprocal of the highest dilution of serum giving a 4+ fixation.

data suggested that more extensive investigation of the meningococcal antibody level of the serum may contribute to the understanding of the epidemiology of meningococcal disease. The CF antigen described in this report seems to possess the sensitivity and the group specificity required of an antigen to be employed in epidemiological studies. This is supported by the results in Tables III and IV. These data indicate that

TABLE V. Comparison of CF *N. meningitidis* Seroconversions* to Isolations in a Recruit Company in Training from 6 Sept. to 10 Nov. 1967.^b

	CF seroconversions	
	Positive	Negative
Isolate	45	10
No isolate	5	10

* A 4-fold or greater rise in antibody titer.

^b Bacterial sampling was made only at the times of reporting to and graduating from recruit training; 64% of the recruits seroconverted between the fifth and ninth week serum sample, indicating acquisition late in training and perhaps not sufficient time for antibody to be produced before the final serum sample was taken.

antibody to *N. meningitidis*, whether as a result of carrier status or overt disease, reacts equally with the CF antigen described in this report, regardless of the *N. meningitidis* group from which the antigen was made. Also, more than 3000 recruit sera have been tested with this antigen and with a battery of 14 bacterial and viral antigens. The serological response to *N. meningitidis* was independent of responses to viruses and bacteria (15). The latter infections were due to adenovirus types 4 and 7, influenza A and B, rhinovirus, *M. pneumoniae* and streptococci.

Complement fixation tests with the antigen described can now complement the group-specific indirect hemagglutination (IHA) test (11). This would permit examining large populations for *N. meningitidis* infection experience without the more complex and laborious support required by meningococcal isolates (15). The CF test would serve as a screening test for incidence of infection and the IHA test would identify those groups that were present.

This approach should assist in answering the questions concerning meningococcal in-

N. meningitidis COMPLEMENT FIXATION ANTIGEN

fections and disease posed by Thomas *et al.* (2). These questions related to (a) what extent, and what time, antibodies are produced following meningococcal infection, (b) by what serological tests such antibodies may most consistently be demonstrated, (c) what correlation, if any, exists between the development of antibodies and such factors as the severity of infection, the rapidity of recovery, or the biological characteristics of the infecting organism, and (d) what levels of antibody are to be found in the blood of carriers and normal individuals in an epidemic area.

Summary. A simple method for preparing an *N. meningitidis* complement fixing antigen is described. Hyperimmune rabbit *N. meningitidis* antiserum reacted approximately the same with CF antigens made from several *N. meningitidis* groups or strains. Recruits known to have become infected with *N. meningitidis* strain Bo during recruit training show equal serological responses to CF antigens made from different *N. meningitidis* groups or strains. Further, 4 recruits who were admitted to the hospital with clinical meningitis also seroconverted equally to any 1 of 6 different *N. meningitidis* CF antigens. Increase in CF titer (4-fold or greater) to *N. meningitidis* correlated significantly with acquisition of meningococcus in the nasopharynx as determined by bacterial isolations.

We are indebted to Miss Patricia Muehl; HMI W. S. Driscoll, USN; Mr. George L. Larson; and HMI T. C. Brewster, USN for their excellent technical assistance.

1. Rake, G. J. *J. Exptl. Med.* 58, 75 (1933).
2. Thomas, L., Smith, H. W., and Dingle, J. H., *J. Clin. Invest.* 22, 361 (1943).
3. Houston, T. and Rankin, J. C., *Brit. Med. J.* 2, 1414 (1907).
4. Bristow, W., Van Pennen, P. F., and Volk, R., *Am. J. Public Health* 55, 1039 (1965).
5. Cruickshank, R., *J. Pathol. Bacteriol.* 52, 142 (1941).
6. Ross, C. A. C. and Stevenson, J., *J. Hyg.* 60, 501 (1962).
7. Sanborn, W. R. and Vedros, N. A., *Health Lab. Sci.* 3, 111 (1966).
8. Singer, R. C., *Med. Clin. N. Am.* 51, 719 (1967).
9. Hollis, D. G., Wiggins, G. L., and Schubert, H. H., *J. Bacteriol.* 95, 1 (1968).
10. Slaterus, K. W., Ruys, A. C., and Sieberg, I. G., *Antonie van Leeuwenhoek, J. Microbiol. Serol.* 29, 265 (1963).
11. Edwards, E. A. and Driscoll, W. S., *Proc. Soc. Exptl. Biol. Med.* 126, 876 (1967).
12. Casey, H. L., *Public Health Serv. Publ. No. 1228*, (1965). *Public Health Monograph No. 74*.
13. Sever, J. L., *J. Immunol.* 88, 320 (1962).
14. Huntley, R. and Reed, D., *Am. J. Epidemiol.* 86, 142 (1967).
15. Edwards, E. A., Rosenbaum, M. J., Pierce, W. E., DeBerry, P., Sullivan, E. J., and Peckinpugh, R. O., *Public Health Rept. (U.S.)* 83, 209 (1968).

Received April 29, 1968. P.S.E.B.M., 1968, Vol. 128.

UNCLASSIFIED

Security Classification

DOCUMENT CONTROL DATA - R&D		
<small>(Security classification of title, body of abstract and indexing annotation must be entered when the overall report is classified)</small>		
1. ORIGINATING ACTIVITY (Corporate author) Naval Medical Research Unit No. 4 Great Lakes, Illinois 60088		2a. REPORT SECURITY CLASSIFICATION Unclassified
		2b. GROUP
3. REPORT TITLE A Genus Specific Complement Fixation Antigen From <u>Neisseria meningitidis</u>		
4. DESCRIPTIVE NOTES (Type of report and inclusive dates)		
5. AUTHOR(S) (Last name, first name, initial) Edwards, E. A. and Devine, L. F.		
6. REPORT DATE Aug-Sept 1968	7a. TOTAL NO. OF PAGES 6	7b. NO. OF REFS 15
8a. CONTRACT OR GRANT NO. a. PROJECT NO. M 4305.01-1001 c. d.		8b. ORIGINATOR'S REPORT NUMBER(S) RU 68.3 9b. OTHER REPORT NO(S) (Any other numbers that may be assigned this report)
10. AVAILABILITY/LIMITATION NOTICES Unlimited distribution		
11. SUPPLEMENTARY NOTES		12. SPONSORING MILITARY ACTIVITY Bureau of Medicine and Surgery Navy Department Washington, D. C.
13. ABSTRACT A simple method for preparing an <u>N. meningitidis</u> complement fixing antigen is described. Hyperimmune rabbit <u>N. meningitidis</u> antiserum reacted approximately the same with CF antigens made from several <u>N. meningitidis</u> groups or strains. Recruits known to have become infected with <u>N. meningitidis</u> strain Bo during recruit training show equal serological responses to CF antigens made from 5 different <u>N. meningitidis</u> groups or strains. Further, 4 recruits who were admitted to the hospital with clinical meningitis also seroconverted equally to any 1 of 6 different <u>N. meningitidis</u> CF antigens. Increase in CF titer (4-fold or greater) to <u>N. meningitidis</u> correlated significantly with acquisition of meningococcus in the nasopharynx as determined by bacterial isolations.		

DD FORM 1 JAN 64 1473

UNCLASSIFIED

Security Classification

UNCLASSIFIED

Security Classification

14. KEY WORDS	LINK A		LINK B		LINK C	
	ROLE	WT	ROLE	WT	ROLE	WT
1. <u>Neisseria meningitidis</u> antibodies						
2. Complement fixing antigen						
3. Meningococcal grouping antisera						

INSTRUCTIONS

1. **ORIGINATING ACTIVITY:** Enter the name and address of the contractor, subcontractor, grantee, Department of Defense activity or other organization (cooperate author) issuing the report.

2a. **REPORT SECURITY CLASSIFICATION:** Enter the overall security classification of the report. Indicate whether "Restricted Data" is included. Marking is to be in accordance with appropriate security regulations.

2b. **GROUP:** Automatic downgrading is specified in DoD Directive 5200.10 and Armed Forces Industrial Manual. Enter the group number. Also, when applicable, show that optional markings have been used for Group 3 and Group 4 as authorized.

3. **REPORT TITLE:** Enter the complete report title in all capital letters. Titles in all cases should be unclassified. If a meaningful title cannot be selected without classification, show title classification in all capitals in parentheses immediately following the title.

4. **DESCRIPTIVE NOTES:** If appropriate, enter the type of report, e.g., interim, progress, summary, annual, or final. Give the inclusive dates when a specific reporting period is covered.

5. **AUTHOR(S):** Enter the name(s) of author(s) as shown on or in the report. Enter last name, first name, middle initial. If military, show rank and branch of service. The name of the principal author is an absolute minimum requirement.

6. **REPORT DATE:** Enter the date of the report as day, month, year, or month, year. If more than one date appears on the report, use date of publication.

7a. **TOTAL NUMBER OF PAGES:** The total page count should follow normal pagination procedures, i.e., enter the number of pages containing information.

7b. **NUMBER OF REFERENCES:** Enter the total number of references cited in the report.

8a. **CONTRACT OR GRANT NUMBER:** If appropriate, enter the applicable number of the contract or grant under which the report was written.

8b, 8c, & 8d. **PROJECT NUMBER:** Enter the appropriate military department identification, such as project number, subproject number, system number, task number, etc.

9a. **ORIGINATOR'S REPORT NUMBER(S):** Enter the official report number by which the document will be identified and controlled by the originating activity. This number must be unique to this report.

9b. **OTHER REPORT NUMBER(S):** If the report has been assigned any other report numbers (either by the originator or by the sponsor), also enter this number(s).

10. **AVAILABILITY/LIMITATION NOTICES:** Enter any limitations on further dissemination of the report, other than those

imposed by security classification, using standard statements such as:

- (1) "Qualified requesters may obtain copies of this report from DDC."
- (2) "Foreign announcement and dissemination of this report by DDC is not authorized."
- (3) "U. S. Government agencies may obtain copies of this report directly from DDC. Other qualified DDC users shall request through _____."
- (4) "U. S. military agencies may obtain copies of this report directly from DDC. Other qualified users shall request through _____."
- (5) "All distribution of this report is controlled. Qualified DDC users shall request through _____."

If the report has been furnished to the Office of Technical Services, Department of Commerce, for sale to the public, indicate this fact and enter the price, if known.

11. **SUPPLEMENTARY NOTES:** Use for additional explanatory notes.

12. **SPONSORING MILITARY ACTIVITY:** Enter the name of the departmental project office or laboratory sponsoring (paying for) the research and development. Include address.

13. **ABSTRACT:** Enter an abstract giving a brief and factual summary of the document indicative of the report, even though it may also appear elsewhere in the body of the technical report. If additional space is required, a continuation sheet shall be attached.

It is highly desirable that the abstract of classified reports be unclassified. Each paragraph of the abstract shall end with an indication of the military security classification of the information in the paragraph, represented as (TS), (S), (C), or (U).

There is no limitation on the length of the abstract. However, the suggested length is from 150 to 225 words.

14. **KEY WORDS:** Key words are technically meaningful terms, or short phrases that characterize a report and may be used as index entries for cataloging the report. Key words must be selected so that no security classification is required. Identifiers, such as equipment model designation, trade name, military project code name, geographic location, may be used as key words but will be followed by an indication of technical context. The assignment of links, roles, and weights is optional.